Being Specific About Race-Specific Medicine
Jonathan D. Kahn
Hamline University School of Law
University of Pennsylvania - School of Medicine
Health Affairs, Vol. 25, 2006
This article is a response to Gary Puckrein's paper "BiDil: From Another Vantage Point," which misrepresents rather than refutes our previously published analysis of BiDil. Puckrein claims that if our analysis were to prevail, patients would be denied life-saving therapy. Any reasonable reading of our paper suggests exactly the opposite. Indeed, based on the evidence, we urge doctors to prescribe the generics or BiDil itself as they see fit, but without regard to the race of their patient.
Number of Pages in PDF File: 3
Keywords: Business of Health, Consumer Issues, Demography, Ethical Issues, Legal/Regulatory Issues, Minority Health, Pharmaceuticals
JEL Classification: D40, I11, I18, K10, K23, L65Accepted Paper Series
Date posted: August 30, 2006
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo2 in 0.344 seconds